AI startup Higgsfield's rapid growth was driven by aggressive, sometimes deceptive tactics. The company used influencers to circulate stock footage disguised as AI output and allegedly distributed controversial deepfakes to generate buzz. This serves as a cautionary tale about the reputational risks of a 'growth at all costs' strategy in the hyper-competitive AI space.

When longevity influencer Bryan Johnson publicizes his use of high-dose psychedelics, he creates a risky 'survivorship bias.' His massive audience may only see his curated, successful experience and attempt to replicate it without his resources or preparation, ignoring the unseen negative outcomes others have faced with similar protocols.

A key hurdle in psychedelic trials is that patients often know if they received the active drug. The industry is addressing this "functional unblinding" by aiming for therapeutic effects so large in Phase 3 that they significantly outweigh any potential placebo bias, making the unblinding issue less critical for approval.

AI video startup Higgs Field deliberately uses shocking content, misleading marketing (like passing stock video as AI), and controversial social media strategies to generate attention. This "rage bait" approach has fueled explosive revenue growth to a $300M run rate in under a year, but also exposes the company to significant backlash and platform risk.

AG1 made a strategic shift from influencer-led marketing to a science-first approach. The company invested over $10 million in double-blind, placebo-controlled human trials and built campaigns around this scientific validation. This move aims to build deep credibility and differentiate the brand in a crowded, often unsubstantiated market.

Even when an influencer genuinely loves a product, the "paid partnership" disclosure creates consumer skepticism. This trend diminishes the power of traditional influencers, making authentic user-generated content and genuine testimonials a more trusted source for marketing.

Shkreli dismisses BPC-157 by applying a pharma diligence framework: questioning its origin (a single researcher), lack of independent verification, implausible physiological basis, and history of failed clinical trials. This provides a clear checklist for evaluating fringe medical compounds from an industry insider's perspective.

The internet directly links Chinese chemical factories with online influencers and consumers. This ecosystem is supercharged by public access to scientific databases like PubMed, which allows for a "weird mix of plausible biological speculation" to be presented as credible science, bypassing all regulatory safeguards.

In an era of scientific skepticism, companies must clearly separate general biomedical education from product-specific promotional data. Blurring these lines undermines their role as credible stewards of science, deepens the patient trust gap, and makes them appear self-serving rather than educational.